Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children

被引：0

作者：

Chee Fu Yung

Xiangmei Ma

Yin Bun Cheung

Bee Khiam Oh

Sally Soh

Koh Cheng Thoon

机构：

[1] KK Women’s and Children’s Hospital,Infectious Disease Service

[2] Nanyang Technological University,Lee Kong Chian School of Medicine

[3] Duke-NUS Medical School,Centre for Quantitative Medicine

[4] Duke-NUS Medical School,Tampere Center for Child Health Research

[5] University of Tampere and Tampere University Hospital,Yong Loo Lin School of Medicine

[6] Vigilance Branch,undefined

[7] Health Products Regulation Group,undefined

[8] Health Sciences Authority,undefined

[9] National University of Singapore,undefined

[10] 1E Kent Ridge Road,undefined

[11] National University Health System Building (NUH),undefined

来源：

Scientific Reports | / 9卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Kawasaki disease (KD) is a systemic vasculitis mainly affecting young children and the leading cause of acquired heart disease in developed countries. We performed a self-controlled case series analysis to investigate the association between PCV13 and KD. All hospitalized KD cases <2 y old from our hospital in Singapore from 2010 to 2014 were included. Complete KD cases were classified based on the definitions of the American Heart Association. During the study period, 288 KD cases were identified. A total of 21 KD cases (12 were classified as Complete KD) had date of onset within the risk interval of day 1 to day 28 post PCV13. The age-adjusted Relative Incidence (RI) for KD following PCV13 dose 1, dose 2 and dose 3 were 1.40 (95% CI, 0.72 to 2.71), 1.23 (95% CI, 0.62 to 2.44) and 0.34 (95% CI, 0.08 to 1.40) respectively. There were seven Complete KD cases with onset during the risk interval after dose 1 of PCV13 (age-adjusted RI 2.59, 95% confidence interval (CI), 1.16 to 5.81). We did not detect a significant increased risk for overall KD among PCV13 recipients.

引用

共 27 条

[1]

McCrindle BW(2017)Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association Circulation. 135 e927-e999

[2]

Uehara R(2012)Epidemiology of Kawasaki disease in Asia, Europe, and the United States J Epidemiol. 22 79-85

[3]

Belay ED(2008)Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction–eight states, 1998–2005 Morb Mortal Wkly Rep. 57 144-148

[4]

Moore MR(2015)Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance Lancet Infect Dis. 15 301-309

[5]

Nuorti JP(2010)Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 59 1-18

[6]

Whitney CG(2009)Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between kawasaki disease and seven-valent pneumococcal conjugate vaccine Pediatr Infect Dis J. 28 438-440

[7]

Center KJ(2013)Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children Vaccine. 31 2578-2583

[8]

Hansen JR(2009)Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990–2007 Pediatr Infect Dis J. 28 943-947

[9]

Lewis E(2006)Tutorial in biostatistics: the self-controlled case series method Stat Med. 25 1768-1797

[10]

Fireman BH(2014)Active surveillance of adverse events following childhood immunization in Singapore Vaccine. 32 5000-5005

← 1 2 3 →